Do you need a Texas-based partner for your CPRIT grant?
Interested in our services?

Vaccine Manuscripts

  1. Mittendorf EA, Clinton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014 Jun6 [Epub ahead of print].
  2. Schneble EJ, Berry JS, Trappey FA, Clinton GT, Ponniah S, Mittendorf E, Peoples GE. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVaxTM) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy 2014 May;6(5):519-31.
  3. Schneble EJ, Yu X, Wagner T, Peoples GE. Novel dendritic cell-based vaccination in late stage melanoma. Hum Vaccin Immunother 2014;10(11): [Epub ahead of print].
  4. Perez SA, Peoples GE, Papamichail M, Baxevanis CN. Invariant chain-peptide fusion vaccine using HER-2/neu. Methods Mol Biol 2014;1139:321-36.
  5. Peoples GE. Rethinking cancer vaccines to avoid T-cell traps. Immunotherapy 2013;5(7):665-8.
  6. Hale DF, Clifton GT, Sears AK, Vreeland TJ, Shumway N, Peoples GE, Mittendorf EA. Cancer vaccines: should we be targeting patients with less aggressive disease? Expert Rev Vaccines 2012;11:721-31.
  7. Clive KS, Tyler JA, Clifton GT, Holmes JP, Ponniah S, Peoples GE, Mittendorf EA. The GP2 peptide: a HER2/neu-based breast cancer vaccine. J Surg Oncol 2012;105:452-8.
  8. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: From US Military Cancer Institute Clinical Trials Group Study I-01 and I- Cancer 2012;118:2594-602.
  9. Vreeland TJ, Hale DF, Clifton GT, Sears AK, Mittendorf EA, Peoples GE. Peptide vaccine strategies in the treatment of cancer. J Proteomics Bioinform 2013 Apr 25;6(4):081-84.
  10. Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther 2011;11:1543-50.
  11. Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev Vacc 2011;10:755-74.
  12. Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Comparison of different HER2/neu vaccines adjuvant breast cancer clinical trials: implications for dosing of peptide vaccines. Expert Rev Vacc 2011;10:201-10.
  13. Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S, Peoples GE. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2011;117:463-17.
  14. Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class I HER2/neu (AE37) peptide. Vaccine 2010;28:7476-82.
  15. Clifton T, Pappas JA, Pavlik M, Papay D, Holmes JP, Ponniah S, Peoples GE. Cancer Vaccine Development Program Collaborations. Mil Med 2010;175 (7 Suppl):54-6.
  16. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Exp Rev Vaccines 2010;9:519-25.
  17. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papmichail M, Baxevanis CN. A new era in anticancer peptide vaccines. Cancer 2010;116:2071-80.
  18. Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg 2010;210:140-7.
  19. Carmichael MG, Benavides LC, Holmes JP, JD, Mittendorf EA, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study 1-04. Cancer 2010;116:292-301.
  20. Peoples GE. HER2 vaccination in high-risk breast cancer. Clin Adv Hematol Oncol 2009;7:715-17.
  21. Shumway NM, Mittendorf EA, Ponniah S, Peoples GE, Murray JL. Therapeutic breast cancer vaccines: a new immunotherapeutic strategy for early-stage disease. BioDrugs 2009;23:277-87.
  22. Mine T, Ferrone S, Vlastos G, Peoples GE, Ioannides CG. Working hypothesis: Elimination of cancer stem cells in solid tumors by immuno-gene therapy using cancer vaccines and created- inhibitory RNA. Curr Cancer Ther Rev 2009;5:217-26.
  23. Benavides LC, Gates JD, Carmichael MG, Patel R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE. The impact of HER2/neu expression level on response to the E75 Vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009;15:2895-904.
  24. Gates, JD, Carmichael MG, Benavides LC, Holmes JP, Hueman MT, Woll MM, Ioannides CG, Robson CH, McLeod DG, Ponniah S, Peoples GE. Long-term follow-up assessment of a HER2/neu peptide (E75) vaccine for the prevention of recurrence in high-risk prostate cancer patients. J Am Coll Surg 2009;208:193-201.
  25. Li Y, Matsueda S, Efferson CL, Tsuda N, Kawano K, Gao H, Peoples GE, Ioannides CG.   Distinct patient responses to activation of T cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines. Anticancer Res 2009;29:41-58.
  26. Mittendorf EA, Holmes JP, Murray JL, Peoples GE. CD4+ T cells in antitumor immunity: utility of an Ii-Key hybrid preventive HER2/neu peptide (AE37) vaccine. Expert Opin Biol Ther 2009;9:71-8.
  27. Amin A, Benavides LC, Holmes JP, Gates JD, Hueman MT, Carmichael MG, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Assessment of immunologic response and pathologic patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide (E75) vaccine. Cancer Immunol Immunoth 2008;57:1817-25.
  28. Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Optimal dose and schedule of a HER2/neu (E75) peptide vaccine in disease-free breast cancer patients. Cancer 2008;113:1666-75.
  29. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunoth 2008;57:1511-21.
  30. Gates JD, Benavides LC, Stojadinovic A, Mittendorf EA, Holmes JP, Carmichael MG, McCall S, Milford AL, Merrils GA, Ponniah S, Peoples GE. Monitoring circulating tumor cells in cancer vaccine trials. Hum Vaccin 2008;4389-92.
  31. Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03. J Clin Oncol 2008; 26: 3426-33.
  32. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-01&I-02. Clin Cancer Res 2008;14:797-803.
  33. Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer. Ann Surg Oncol 2007;14:3359-68.
  34. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer 2007;110:1677-86.
  35. Dehqanzada ZA, Storrer CE, Hueman MT, Foley R, Harris K, Shriver CD, Ponniah S, Peoples GE. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technology. Oncol Rep 2007;17:687-94.
  36. Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney J, Shriver CD, Ponniah S, Peoples GE. Analysis of naїve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immun Immunoth 2007;56:135-46.
  37. Mittendorf EA, Peoples GE. HER2/neu peptide breast cancer vaccines: Current status and future directions. Breast Diseases: A Year Book Quarterly 2007;17:318-20.
  38. Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in early stage breast cancer patients. Surgery 2006;139:407-18.
  39. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Sur Oncol 2006;13:1085-98.
  40. Hueman MT, Stojadinovic A, Storrer CE, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Levels of circulating regulatory CD4+CD25+ T cells are decreasing in breast cancer patients after vaccination with a HER2/neu peptide (E75) vaccine. Br Cancer Res Treat 2006;98:17-29.
  41. Mittendorf EA, Storrer CE, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006;106:2309-17.
  42. Khoo S, Ponniah S, Peoples GE. HER2/neu vaccines in breast cancer. Women’s Health (Lond Engl) 2006;2:217-23.
  43. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE. Correlations between serum MCP-1 levels, clinical prognostic factors, and HER2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006;12:478-86.
  44. Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high risk breast cancer patients. J Clin Oncol 2005;23:7536-45.
  45. Mittendorf MA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Br Cancer Res Treat 2005;92:85-93.
  46. Woll MM, Hueman MT, Ryan GB, Ioannides CG, Henderson CG, Sesterhan I, Shrivasta S, McLeod DG, Moul JW, Peoples GE. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. Intl J Oncol 2004;25:1769-80.
  47. Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE. Direct measurement of peptide specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J Clin Immunol 2004;24:449-61.
  48. Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 2003;9:3222-34.
  49. Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG. Vaccine implications of a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res 1999;5:4214-23.